Test Price
1,700 AED✅ Home Collection Available
Breast Biopsy (Modified Radical Mastectomy) with ER, PR, HER2/neu, Ki‑67 Panel in UAE | 1700 AED | 2026 DHA Guidelines
تحليل خزعة الثدي (استئصال جذري معدل) مع لوحة ER و PR و HER2/neu و Ki‑67 في الإمارات | 1700 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- 99.9% Diagnostic Sensitivity via ISO‑accredited IHC, backed by double‑blind histopathological interpretation.
- VIP Home Collection (8 AM–11 PM) – hospital‑grade cold‑chain transport included, nurse‑led sample validity guarantee.
- Telephonic Post‑Test Clinical Correlation – a senior pathologist explains your receptor profile.
- Insurance Direct Billing – WhatsApp +971 54 548 8731 for eligibility verification.
ملخص تنفيذي: لوحة مستقبلات الورم من خزعة الثدي توفر تقييماً دقيقاً لحالة مستقبلات الإستروجين والبروجسترون و HER2/neu و Ki‑67، مما يوجه علاجاً شخصياً وفق أحدث إرشادات الأورام. فائقة الحساسية، معتمدة من الهيئات التنظيمية، وتنقل بارداً مرخصاً.
Clinical Overview & Test Comparison
This advanced tissue‑based panel is the gold standard for breast cancer subtyping following a modified radical mastectomy. It simultaneously quantifies oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu), and the proliferation marker Ki‑67, enabling precise oncologic decision‑making and eligibility for targeted therapies.
تعد لوحة المؤشرات الحيوية النسيجية المعيار الذهبي لتصنيف سرطان الثدي، وتجمع بين دقة الكيمياء النسيجية المناعية وتحديد كمي للمستقبلات.
| Feature | Our Test (DHA/ISO) | Routine Biopsy |
|---|---|---|
| Methodology | IHC + Digital Pathology | H&E Only |
| Precision | 99.9% Sensitivity | Variable |
| Turnaround | 6 Days (Cold‑Chain) | 7–14 Days |
| Therapeutic Guidance | Full receptor & Ki‑67 profile | None |
Physician Insight & Safety Protocol
“A complete receptor panel, including Ki‑67 proliferation index, is not merely a prognostic indicator; it directly determines candidacy for hormonal therapy, anti‑HER2 agents, and chemotherapy. Always correlate these findings with tumour grade, nodal status, and comprehensive imaging. In the post‑mastectomy context, this analysis defines the roadmap for adjuvant therapy.”
— Dr. Prabhakar Reddy, Surgical Oncologist, DHA License 61713011
⚠ Medication Safety Alert
Do not discontinue any prescribed medication (including tamoxifen or aromatase inhibitors) without direct consultation with your oncologist. Receptor status guides but does not independently dictate immediate therapy changes.
Exclusion Criteria & Emergency Red Flags
- Active infection or open wound at the biopsy site.
- Uncorrected severe coagulopathy (INR > 2.0, platelets < 50,000/μL).
- Pregnancy – tissue sampling should be deferred unless maternal oncologic urgency outweighs fetal risk.
- Red Flags post‑biopsy: excessive bleeding, rapidly expanding hematoma, fever > 38°C, or purulent discharge – seek immediate ER care.
- Patient refusal or inability to provide informed consent; specimen integrity compromised by prolonged ischemia (> 30 minutes before fixation).
Patient FAQ & Clinical Guidance
What does the ER, PR, HER2/neu, Ki‑67 panel detect?
This test precisely evaluates oestrogen, progesterone, HER2/neu, and Ki‑67 receptor status on biopsied breast cancer tissue.
The panel uses immunohistochemistry on formalin‑fixed paraffin‑embedded sections to stain for hormone receptors and HER2 overexpression, while Ki‑67 is scored as a percentage of proliferating tumour cells. Results classify your cancer into luminal A, luminal B, HER2‑enriched, or basal‑like subtypes — directly influencing hormonal therapy, Herceptin eligibility, and chemotherapy decisions.
ما الذي تكشفه هذه اللوحة؟ تقيس بدقة مستقبلات الإستروجين والبروجسترون و HER2/neu ومؤشر Ki‑67 في نسيج سرطاني مأخوذ بالخزعة، مما يحدد النمط الجزيئي للورم ويوجه العلاج المناعي والكيماوي.
Why is Ki‑67 reported with hormone receptors?
Ki‑67 proliferation index differentiates indolent luminal A cancers from aggressive luminal B, altering chemotherapy recommendations.
Without Ki‑67, ER+/PR+ tumours may be misclassified as low risk. A high Ki‑67 (>20%) in a hormone‑receptor positive case often triggers adjunctive chemotherapy even when HER2 is negative. Thus the quadruple assay prevents undertreatment and overtreatment simultaneously.
لماذا يُرفق مؤشر Ki‑67؟ يميّز معدل التكاثر العالي ويحدد الحاجة إلى العلاج الكيماوي إلى جانب الهرموني، متفادياً نقص أو زيادة العلاج.
Can I do this test before surgery?
Core needle biopsy tissue can be used for the receptor panel, but a formal mastectomy specimen provides maximal tissue representation and accuracy.
Pre‑surgical biopsies allow neoadjuvant therapy planning. However, when complete mastectomy tissue is available, our test reduces sampling error and provides definitive receptor staining across the whole tumour. Your surgical oncologist will decide the optimal specimen type.
هل يمكن إجراء الاختبار قبل الجراحة؟ يمكن استخدام خزعة بالإبرة الأساسية، لكن العينة الكاملة من الاستئصال الجذري تعطي دقة أعلى لتمثيل كل الورم.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians